无创性指标对肝硬化临床终点事件的预测

徐铭益; 徐梓馨

doi:10.3969/j.issn.1001-5256.2020.09.006

无创性指标对肝硬化临床终点事件的预测

DOI: 10.3969/j.issn.1001-5256.2020.09.006

上海交通大学附属第一人民医院消化科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1220
- HTML全文浏览量: 43
- PDF下载量: 159
- 被引次数: 0
出版历程
- 收稿日期: 2020-04-29
- 出版日期: 2020-09-20

Value of noninvasive indicators in predicting clinical outcome events of liver cirrhosis

Xu MingYi,
Xu ZiXin

Department of Gastroenterology,The First People's Hospital Affiliated to Shanghai Jiao Tong University

摘要

摘要: 目前关于肝硬化的无创诊断指标的研究越来越多,但其与肝硬化临床终点事件的关系以及预测价值尚未有统一。针对血清学指标、血清诊断模型、肝硬度值(LSM)等无创性指标在肝硬化临床终点事件预测中的价值进行归纳。血清指标(PLT、FibroTest等)结合LSM的无创诊断方法可评估肝纤维化分期,也能较好的预测肝硬化终点事件及远期预后,已被写入国内外指南中广泛应用于临床。采用新的组合(比如LSM联合血清指标或诊断模型)或逐步计算法可展现出改良的希望,从而实现患者的个体化动态临床管理,减少或避免肝硬化临床终点事件的发生,使肝硬化患者最大获益。
- 肝硬化 /
- 生物标记 /
- 弹性成像技术
Abstract: At present,more and more studies have been conducted on noninvasive diagnostic indicators for liver cirrhosis,but no consensus has been reached on the association of noninvasive diagnostic indicators with clinical outcome events and their predictive value. This article summarizes the value of noninvasive indicators,including serological markers,serum diagnostic models,and liver stiffness measurement( LSM),in predicting the clinical outcome events of liver cirrhosis. The noninvasive diagnostic method of serological markers( such as platelet count and FibroTest) combined with LSM can assess the stage of liver fibrosis and predict the outcome events and long-term prognosis of liver cirrhosis,and thus it has been included in Chinese and global guidelines and has been widely used in clinical practice. The use of new combinations( such as LSM combined with serological markers or diagnostic models) or a step-by-step calculation method shows the hope of modification to realize individualized dynamic clinical management of patients,reduce or avoid the occurrence of clinical outcome events of liver cirrhosis,and bring maximum benefit to patients with liver cirrhosis.
- liver cirrhosis /
- biomarkers /
- elasticity imaging techniques

HTML全文

参考文献(55)

[1] GUDOWSKA M,GRUSZEWSKA E,PANASIUK A,et al. Hyaluronic acid concentration in liver diseases[J]. Clin Exp Med,2016,16(4):523-528.

[2] QI X,LIU X,ZHANG Y,et al. Serum liver fibrosis markers in the prognosis of liver cirrhosis:A prospective observational study[J]. Med Sci Monit,2016,22:2720-2730.

[3] QI X,LI H,CHEN J,et al. Serum liver fibrosis markers for predicting the presence of gastroesophageal varices in liver cirrhosis:A retrospective cross-sectional study[J]. Gastroenterol Res Pract,2015,2015:274534.

[4] ZHU M,HAN M,XIAO X,et al. Dynamic differences of red cell distribution width levels contribute to the differential diagnosis of hepatitis B virus-related chronic liver diseases:A case-control study[J]. Int J Med Sci,2019,16(5):720-728.

[5] HALIM MH,ABDULLA NA,KAMEL A,et al. Significance of growth differentiation factor 15 in chronic HCV patients[J]. J Genet Eng Biotechnol,2017,15(2):403-407.

[6] ELAGHORI A,SALEM PES,AZZAM E,et al. Ghrelin level in patients with liver C cirrhosis[J]. Acta Endocrinol(Buchar),2019,5(1):62-68.

[7] TORNAI T,VITALIS Z,SIPEKI N,et al. Macrophage activation marker,soluble CD163,is an independent predictor of shortterm mortality in patients with cirrhosis and bacterial infection[J]. Liver Int,2016,36(11):1628-1638.

[8] COLECCHIA A,MARASCO G,TADDIA M,et al. Liver and spleen stiffness and other noninvasive methods to assess portal hypertension in cirrhotic patients:A review of the literature[J]. Eur J Gastroenterol Hepatol,2015,27(9):992-1001.

[9] WAIDMANN O,BRUNNER F,HERRMANN E,et al. Macrophage activation is a prognostic parameter forvariceal bleeding and overall survival in patients with liver cirrhosis[J]. J Hepatol,2013,58(5):956-961.

[10] HAMETNER S,FERLITSCH A,FERLITSCH M,et al. The VITRO score(Von Willebrand Factor Antigen/Thrombocyte Ratio)as a new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including ELF test[J]. PLo S One,2016,11(2):e0149230.

[11] DING XC,MA WL,LI MK,et al. A Meta-analysis of the value of vWF in the diagnosis of liver cirrhosis with portal hypertension[J]. J Clin Transl Hepatol,2019,7(1):3-8.

[12] FUJITA K,NIKI T,NOMURA T,et al. Correlation between serum galectin-9 levels and liver fibrosis[J]. J Gastroenterol Hepatol,2018,33(2):492-499.

[13] EDOO MIA,CHUTTURGHOON VK,WUSU-ANSAH GK,et al. Serum biomarkers AFP,CEA and CA199 combined detection for early diagnosis of hepatocellular carcinoma[J]. Iran J Public Health,2019,48(2):314-322.

[14] JANG ES,JEONG SH,KIM JW,et al. Diagnostic performance of alpha-fetoprotein,protein induced by vitamin k absence,osteopontin,dickkopf-1 and its combinations for hepatocellular carcinoma[J]. PLo S One,2016,11(3):e0151069.

[15] LIU Z,WU M,LIN D,et al. Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma[J]. J Int Med Res,2020,48(2):300060520902575.

[16] WANG S,ZHANG W,ZHANG F,et al. Correlation between FibroScan,APRI Detecting the degree of esophageal and gastric varices of liver cirrhosis[J]. Chin J Hepatol,2018,26(5):342-346.(in Chinese)王帅，张威，张帆，等．FibroScan和APRI对肝硬化食管胃底静脉曲张程度的预测价值[J]．中华肝脏病杂志，2018,26(5):342-346.

[17] NG KJ,TSENG CW,CHANG TT,et al. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin[J]. Clin Interv Aging,2016,11:1035-1041.

[18] KOTHARI HG,GUPTA SJ,GAIKWAD NR,et al. Role of non-invasive markers in prediction of esophageal varices and variceal bleeding in patients of alcoholic liver cirrhosis from central India[J]. Turk J Gastroenterol,2019,30(12):1036-1043.

[19] COLLI A,GANA JC,YAP J,et al. Platelet count,spleen length,and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis[J]. Cochrane Database Syst Rev,2017,4:CD008759.

[20] FARID K,OMRAN MM,FARAG RE,et al. Development and evaluation of a novel score for prediction of large oesophageal varices in patients with hepatitis C virus-induced liver cirrhosis[J]. Br J Biomed Sci,2017,74(3):138-143.

[21] NGO Y,MUNTEANU M,MESSOUS D,et al. A prospective analysis of the prognostic value of biomarkers(FibroTest)in patients with chronic hepatitis C[J]. Clin Chem,2006,52(10):1887-1896.

[22] FRIEDRICH-RUST M,ONG MF,MARTENS S,et al. Performance of transient elastography for the staging of liver fibrosis:A meta-analysis[J]. Gastroenterology,2008,134(4):960-974.

[23] CHON YE,CHOI EH,SONG KJ,et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B:A meta-analysis[J]. PLo S One,2012,7(9):e44930.

[24] GARCIA-TSAO G,ABRALDES JG,BERZIGOTTI A,et al.Portal hypertensive bleeding in cirrhosis:Risk stratification,diagnosis,and management:2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology,2017,65(1):310-335.

[25] de FRANCHIS R,Baveno VI Faculty. Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol,2015,63(3):743-752.

[26] TRIPATHI D,STANLEY AJ,HAYES PC,et al. U. K. guidelines on the management of variceal haemorrhage in cirrhotic patients[J]. Gut,2015,64(11):1680-1704.

[27] LEE HW,CHON YE,KIM SU,et al. Erratum:Predicting liver-related events using transient elastography in chronic hepatitis C patients with sustained virological response[J]. Gut Liver,2016,10(4):653-655.

[28] HONG WK,KIM MY,BAIK SK,et al. The usefulness of noninvasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients:Korean data[J]. Clin Mol Hepatol,2013,19(4):370-375.

[29] LEE JG,SOHN JH,JEONG JY,et al. Combined effect of hepatic venous pressure gradient and liver stiffness on longterm mortality in patients with cirrhosis[J]. Korean J Intern Med,2020,35(1):88-98.

[30] LEE JI,LEE HW,KIM SU,et al. Follow-up liver stiffness measurements after liver resection influence oncologic outcomes of hepatitis-B-associated hepatocellular carcinoma with liver cirrhosis[J]. Cancers(Basel),2019,11(3):425.

[31] Review Panel for Liver Stiffness Measurement. Recommendations for the clinical application of transient elastography in liver fibrosis assessment[J]. Chin J Hepatol,2013,21(6):420-424.(in Chinese)肝脏硬度评估小组．瞬时弹性成像技术诊断肝纤维化专家意见[J]．中华肝脏病杂志，2013,21(6):420-424.

[32] STEFANESCU H GM,LUPSOR M,et al. Spleen stiffness measurement using Fibroscan for the noninvasive assessment of esophageal varices in liver cirrhosi patients[J]. Gastroenterol Hepatol,2011,26:164-170.

[33] ANTONIO COLECCHIA RS,ALESSANDRO CUCCHETTI,et al. Prognostic factors for hepatocellular carcinoma recurrence[J]. World J Gastroemterol,2014,20:5935-5950.

[34] TSENG Y,LI F,WANG J,et al. Spleen and liver stiffness for noninvasive assessment of portal hypertension in cirrhotic patients with large esophageal varices[J]. J Clin Ultrasound,2018,46(7):442-449.

[35] NIERHOFF J,CHVEZ ORTIZ AA,HERRMANN E,et al. The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis:A meta-analysis[J]. Eur Radiol,2013,23(11):3040-3053.

[36] BOTA S,HERKNER H,SPOREA I,et al. Meta-analysis:ARFI elastography versus transient elastography for the evaluation of liver fibrosis[J]. Liver Int,2013,33(8):1138-1147.

[37]爦IRLI R,SPOREA I,POPESCU A,et al. Ultrasound-based elastography for the diagnosis of portal hypertension in cirrhotics[J]. World J Gastroenterol,2015,21(41):11542-11551.

[38] SALZL P,REIBERGER T,FERLITSCH M,et al. Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index[J]. Ultraschall Med,2014,35(6):528-533.

[39] ATTIA D,SCHOENEMEIER B,RODT T,et al. Evaluation of liver and spleen stiffness with acoustic radiation force impulse quantification elastography for diagnosing clinically significant portal hypertension[J]. Ultraschall Med,2015,36(6):603-610.

[40] CHOI SY,JEONG WK,KIM Y,et al. Shear-wave elastography:A noninvasive tool for monitoring changing hepatic venous pressure gradients in patients with cirrhosis[J]. Radiology,2014,273(3):917-926.

[41] LIN Y,DING H,ZHUANG Y,et al. Expanded clinical verification of effectiveness of two-dimensional-shear wave elastography in the noninvasive evaluation of hepatic fibrosis[J]. Natl Med J China,2018,98(15):1148-1151.(in Chinese)林盈，丁红，庄园，等．剪切波弹性成像新技术无创评估肝纤维化进程有效性的扩大临床验证[J]．中华医学杂志，2018,98(15):1148-1151.

[42] CASSINOTTO C,CHARRIE A,MOURIES A,et al. Liver and spleen elastography using supersonic shear imaging for the non-invasive diagnosis of cirrhosis severity and oesophageal varices[J]. Dig Liver Dis,2015,47(8):695-701.

[43] THIELE M,DETLEFSEN S,SEVELSTED MLLER L,et al.Transient and 2-dimensional shear-wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis[J]. Gastroenterology,2016,150(1):123-133.

[44] VIZZUTTI F,ARENA U,ROMANELLI RG,et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis[J]. Hepatology,2007,45(5):1290-1297.

[45] RYE K,MORTIMORE G,AUSTIN A,et al. Non-invasive diagnosis of oesophageal varices using systemic haemodynamic measurements by finometry:Comparison with other non-invasive predictive scores[J]. J Clin Exp Hepatol,2016,6(3):195-202.

[46] European Association for Study of Liver,Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol,2015,63(1):237-264.

[47] LIANG XE,CHEN YP. Role of liver fibrosis assessment in decision-making and efficacy surveillance for antiviral therapy in patients with chronic hepatitis B[J]. J Clin Hepatol,2016,32(11):2058-2061.(in Chinese)梁携儿，陈永鹏．肝纤维化评估在慢性乙型肝炎抗病毒治疗决策和疗效监测中的作用[J]．临床肝胆病杂志，2016,32(11):2058-2061.

[48] KIM MN,KIM SU,KIM BK,et al. Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir[J]. Liver Int,2014,34(8):1216-1223.

[49] KIM MN,KIM SU,PARK JY,et al. Risk assessment of liverrelated events using transient elastography in patients with chronic hepatitis B receiving entecavir[J]. J Clin Gastroenterol,2014,48(3):272-278.

[50] LEE HW,YOO EJ,KIM BK,et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy[J]. Am J Gastroenterol,2014,109(8):1241-1249.

[51] MAURICE JB,BRODKIN E,ARNOLD F,et al. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices[J]. J Hepatol,2016,65(5):899-905.

[52] WONG GL,CHAN HL,WONG CK,et al. Liver stiffnessbased optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B[J]. J Hepatol,2014,60(2):339-345.

[53] JUNG KS,KIM SU,AHN SH,et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement(FibroScan)[J]. Hepatology,2011,53(3):885-894.

[54] de LEDINGHEN V,VERGNIOL J,BARTHE C,et al. Non-invasive tests for fibrosis and Iiver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus[J].Aliment Pharmacol Ther,2013,37(10):979-988.

[55] WANG JH,YEN YH,YAO CC,et al. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy[J]. Liver Int,2016,36(12):1793-1799.

施引文献

资源附件(0)

访问统计